Trial Results Unclear for Benefit of Longer Hemodialysis Sessions
THURSDAY, April 18, 2019 -- Intervention uptake was insufficient to allow evaluation of its impact in a pragmatic trial designed to assess the effect of longer hemodialysis duration on death and other outcomes; the findings from the Time to Reduce Mortality in ESRD (TiME) trial were published online April 18 in the Journal of the American Society of Nephrology.
Laura M. Dember, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues performed a cluster-randomized, pragmatic trial demonstration project to develop approaches for embedding trials into routine delivery to assess the effects of maintenance hemodialysis session duration. Dialysis facilities randomly assigned to the intervention adopted a default session duration of ≥255 minutes, while those randomly assigned to usual care had no trial-driven approach to duration. Multiple strategies were used to engage facility personnel and participating patients. A total of 7,035 incident patients from 266 dialysis units were enrolled.
The trial was discontinued at a median follow-up of 1.1 years due to an inadequate between-group difference in session duration. The researchers found that mean session durations were 216 and 207 minutes for the intervention and usual care groups, respectively, in the primary analysis population (participants with estimated body water ≤42.5 L). Compared with usual care, there was no reduction in mortality or hospitalization rate for the intervention.
"There is a pressing need for data from randomized trials to guide clinical practice in dialysis," Dember said in a statement. "Pragmatic trials embedded in clinical care delivery have tremendous potential for efficiently producing evidence that is highly generalizable to the nonresearch setting; however, experience with this approach is limited. The TiME trial provides an important foundation for future pragmatic trials in dialysis as well as in other settings."
Several authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: April 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.